-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Janssen announced today that the European Commission (EC) has approved the conditional marketing of Tecvayli (teclistamab), a bispecific antibody targeting B cell maturation antigen (BCMA), for the treatment of adults with relapsed/refractory multiple myeloma (RRMM).
This approval of teclistamab is based on results from the Phase 1/2 MajesTEC-1 trials (NCT03145181 and NCT04557098) in which patients with relapsed/refractory disease received teclistamab at 1.
Multiple myeloma is the second most common hematological malignancy, accounting for about 10% of hematological malignancies
BCMA is a popular target for the treatment of B-cell blood cancers
References: